Miltenyi Biotec Original 200-070-148 CliniMACS TCRα/β-Biotin, 7.5 mL
$4609.54 / Parcel$5531.45 Min.order:1
Brand Sales
The T cell receptor (TCR) is a heterodimer composed of two transmembrane glycoprotein chains, α and β. Both chains are members of the Ig superfamily and consist of a constant and a polymorphic variable region. The variable region of the TCRα/β is involved in recognition of antigenic peptides presented by the MHC complex of antigen-presenting cells. The TCRα/β is expressed on the majority of peripheral blood T cells. The Anti-TCRα/β antibody recognizes a common determinant of the TCRα/β-CD3 compl

Support Payment Term:

HSBC Hong Kong

paypal

Alibaba Pay

Western Union

USD

EUR

GBP

SGD

HKD

CNH

CAD

MXN

BRL

JPY

THB

MOP

AUD

NZD

PLN

CZK

HUF

RON

CHF

SEK

NOK

DKK

TRY

AED

SAR

ILS

ZAR

$0.00

Quantity

Discover similar items

Page 1 of 2

Specifications for CliniMACS® TCRα/β Product Line
Overview
The T cell receptor (TCR) is a heterodimer composed of two transmembrane glycoprotein chains, α and β. Both chains are members of the Ig superfamily and consist of a constant and a polymorphic variable region. The variable region of the TCRα/β is involved in recognition of antigenic peptides presented by the MHC complex of antigen-presenting cells. The TCRα/β is expressed on the majority of peripheral blood T cells. The Anti-TCRα/β antibody recognizes a common determinant of the TCRα/β-CD3 complex.

The CliniMACS® TCRα/β Product Line consists of murine anti-TCRα/β monoclonal antibodies conjugated to biotin.

One vial contains 7.5 mL sterile, non-pyrogenic solution.

The performance of the CliniMACS TCRα/β Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.

Please inquire about required CliniMACS System components and accessories.

Detailed product information
Applications
The CliniMACS TCRα/β Product Line was developed for the depletion of unwanted TCRα/β+ T cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System. This approach maintains the stem cells and immune effector cells, such as NK cells and TCRγ/δ+ T cells, in the cellular product.The CliniMACS TCRα/β Product Line can also be used in combination with the CliniMACS CD19 Reagent to additionally remove the CD19+ B cells from the cellular product.

After labeling of TCRα/β+ cells with CliniMACS TCRα/β-Biotin, CliniMACS Anti-Biotin Reagent is used for the magnetic depletion of TCRα/β+ cells from the cellular product.